Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
Ive been told one of Mr Walt's areas of expertise is securing non-dilutive funding ie grants, sponsorship etc. This is an avenue we have been unable to pursue previously. Submitting an IND app will open such doors.
Im pretty confident Eli Lilly will get their wallets out with some supportive funding when the time is right. Not required just yet mind.
Don’t feed them mate!
The SP is currently ridiculous and EXTREMELY frustrating but the companies progress is excellent.
Someone come on here and tell me what HEMO haven’t done well with the science and the link with Eli Lilly on multiple fronts and I’ll happily debate it. Any chinks or flaws with the commercial prospects? Fire away.
You’d think it might be a takeover target but it doesn’t seem to work like that in pharma. Not usually much hostility between big/junior pharmas working together.
And Eli for me in particular aren’t about that. They’re happy to get the cheque book out and write big numbers providing you can prove it works.
Proof of concept end of phase1/2a trials. Some time around then or in the run up as trial results are monitored I think they’ll be sniffing about.
I remain ultra confident of success at HEMO. The SP is frustrating but will catch up to the intrinsic value at some point. Let’s have a good run into the year end!
Don’t get scared into giving up your shares people.
Underwhelming SP action. Although I expect us to rise over the coming days.
The news is outstanding and validates the quality of HEMOs work. Eli letting us prove it works now before they’ll buy it! Makes sense.
Other projects can be driven forward now the CDX IP deal is done. Predicting a strong Q4 of news and SP positivity.
The awaited RNS should be extremely positive for HEMO. A proper MCAP will be found once the masses realise HEMO have continued to move things along well with GlobalCo and that they still want CDX all ever since the CLN/no option debacle. Such a bloody mess.
Loads of news flow to come.
We’ve had pre news spikes before on the hype and excitement. Zero excitement this time. The market wants to see the news before it reacts.
Hit us with a GlobalCo deal and then we could see things motor a bit.
Haddy I don’t think you understand how well positioned HEMO are. Simple as that. The SP acts irrespective of anything currently. The interim update was fantastic. Imo of course. Not everyone sees that including you it seems.
Sorry so just to conclude
I’ve no idea what impact a CDX deal will have on the SP. But my bets are on it going up though.
My point is my view is there’s a lot more going on that just agreeing the price of the IP with these negotiations.
I think you mis understand the discussion.
I suggest Eli will buy HEMO out down the line. That’s my view. At the appropriate time of course.
Another point is the deal getting done on CDX to secure the IP from GlobalCo going forward so work can continue and in my view see Globalco continue to work with HEMO in some capacity on it. This whole transaction helps to validate HEMO tech if the collab effectively continues into clinical trials.
The SP moved from 9p+ down to 2p for a combo of reasons including CLNs and a ‘no option taken’ RNS re CDX and GlobalCo.
For them to formally officially throw their hat back in the ring, possibly with an Eli Lilly name drop, extending our collab on CDX into clinical trials and therefore extending the potential (and likelihood) of then wanting to buy a successful CDX down the line, I think it is you under estimates the potential content of any milestone and it’s context for HEMO.
I hope they’ll include things like using their labs and scientists to run the trials as a point that may be in the ‘deal’. We shall see.
If you think there have been six months negotiations solely about whether GlobalCo want £1m or £1.5m for their IP i respectively suggest you need to do more research.
Fair dos Bill!
Contrary to belief I try not to just make stuff up.
Yes I called a CDX deal in April and May and it still hasn’t arrived. But I’m 100% certain it will however much longer it will take.
We will be working with Eli Lilly on CDX and the other projects, with CDX finally being made official hopefully in the next few weeks.
The whole dynamics of the situation change when you realise Eli are all the GlobalCo references, multi projects with the same. its only going one way down the line and Eli will have to get there (overly large) wallets out.
Providing the drugs don’t crash and burn of course.
“This is the same GlobalCo” … as for CDX and mice
Then on the 13th July GlobalCo are announced as Eli.
It’s always been Eli. They have their hooks into HEMO on multiple projects… CDX, Lupus, mice…
They buy HEMO after CDX and or CAR T (fundamentally based on similar monoclonal antibodies) reach clinical proof of concept after phase 1/2a trials conclude. Or maybe before if things are going well through the trials.
I’m hopeful Eli will let us use their clinical trial team and help manage the trials as part of the deal.
We will be working together going forward.